The nurse recognizes that adrenergic drugs cause relaxation of the bronchi and bronchodilation by stimulating which type of receptors?
A. Alpha 1 adrenergic
B. Beta2 adrenergic
C. Beta adrenergic
D. Dopaminergic
The Correct answer and Explanation is:
The correct answer is B. Beta2 adrenergic.
Explanation:
Adrenergic drugs, also known as sympathomimetic drugs, mimic the effects of the sympathetic nervous system by activating adrenergic receptors. These receptors are classified into alpha (α) and beta (β) types, which further subdivide into alpha-1, alpha-2, beta-1, beta-2, and beta-3 receptors. Each receptor type has specific physiological effects depending on where they are located in the body.
Beta2 adrenergic receptors are primarily located in the smooth muscle of the lungs, as well as in the blood vessels of skeletal muscles and the uterus. When adrenergic drugs stimulate these receptors, they cause the relaxation of smooth muscle, leading to bronchodilation. This relaxation occurs because Beta2 adrenergic receptor activation increases the production of cyclic adenosine monophosphate (cAMP), a molecule that reduces intracellular calcium levels, thereby relaxing smooth muscles. In the respiratory system, this leads to the dilation of the bronchi and bronchioles, making it easier for air to flow in and out of the lungs. Therefore, Beta2 agonists are commonly used in the treatment of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other bronchospastic disorders.
Beta1 receptors are located primarily in the heart and are responsible for increasing heart rate and the force of heart contractions. Alpha1 receptors are found mostly in blood vessels, where they cause vasoconstriction. Dopaminergic receptors are primarily found in the brain and kidneys, and they influence blood flow and neurotransmission, but they are not involved in bronchodilation.
In clinical practice, drugs such as albuterol and salmeterol, which are Beta2 adrenergic agonists, are used as bronchodilators to treat patients with obstructive airway diseases. These drugs specifically target Beta2 receptors to relieve bronchospasm, improve breathing, and enhance oxygenation. Understanding the role of Beta2 receptors is crucial for the effective management of conditions that require bronchodilation.